Windham Venture Partners is a New York City, New York based venture capital firm. They invest in healthcare companies, with an emphasis on medical technology and digital health.
When they invest, they look for a company to have an experienced and knowledgeable leadership team, an evidence-based technology or procedure which approaches a problem in a new or superior way without intellectual property barriers and a concept past development stage, addressing a large market with impressive data and a clear value proposition.
Windham Venture Partners has made investments in NovellusDx, MC10, Nebula Genomics, Earlens Corporation, Nuvaira, NeuSpera Medical, CVRx, CredSimple, SubjectWell, Science Exchange, Blueprint Health, Cartiva, Coravin and Cureatr.
Adam E. Fine
General Partner & CEO
Lorne Taichman, MD, PhD
Director, Science & Technology
Roger S. Fine
General Partner & Chairman